Trade Kalaris Therapeutics INC - KLRS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.25 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.59 |
| Open | 6.85 |
| 1-Year Change | 838.36% |
| Day's Range | 6.29 - 6.85 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2025 | 6.47 | -0.38 | -5.55% | 6.85 | 6.85 | 6.29 |
| Apr 21, 2025 | 6.59 | -0.17 | -2.51% | 6.76 | 7.25 | 6.32 |
| Apr 17, 2025 | 6.90 | 0.19 | 2.83% | 6.71 | 7.24 | 6.70 |
| Apr 16, 2025 | 6.58 | -0.27 | -3.94% | 6.85 | 6.96 | 6.19 |
| Apr 15, 2025 | 6.36 | -0.26 | -3.93% | 6.62 | 6.85 | 6.00 |
| Apr 14, 2025 | 6.80 | -0.50 | -6.85% | 7.30 | 7.84 | 6.55 |
| Apr 11, 2025 | 7.36 | 0.52 | 7.60% | 6.84 | 7.94 | 6.80 |
| Apr 10, 2025 | 7.30 | -0.44 | -5.68% | 7.74 | 8.07 | 6.76 |
| Apr 9, 2025 | 8.10 | 0.85 | 11.72% | 7.25 | 8.30 | 7.05 |
| Apr 8, 2025 | 7.09 | -0.20 | -2.74% | 7.29 | 7.39 | 6.67 |
| Apr 7, 2025 | 6.33 | -0.47 | -6.91% | 6.80 | 6.99 | 5.67 |
| Apr 4, 2025 | 7.19 | -0.21 | -2.84% | 7.40 | 7.59 | 6.89 |
| Apr 3, 2025 | 7.37 | -0.52 | -6.59% | 7.89 | 8.03 | 7.37 |
| Apr 2, 2025 | 8.04 | 0.10 | 1.26% | 7.94 | 8.35 | 7.89 |
| Apr 1, 2025 | 7.67 | -0.07 | -0.90% | 7.74 | 8.31 | 7.62 |
| Mar 31, 2025 | 7.94 | -0.55 | -6.48% | 8.49 | 8.62 | 7.67 |
| Mar 28, 2025 | 8.48 | -0.41 | -4.61% | 8.89 | 8.98 | 8.46 |
| Mar 18, 2025 | 9.68 | -0.11 | -1.12% | 9.79 | 10.19 | 9.48 |
| Mar 17, 2025 | 9.39 | -0.25 | -2.59% | 9.64 | 9.69 | 9.28 |
| Mar 14, 2025 | 9.63 | 0.29 | 3.10% | 9.34 | 9.65 | 9.28 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
AlloVir, Inc. Company profile
About Allovir Inc
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). Its LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Allovir Inc revenues was not reported. Net loss increased from $69.8M to $172M. Higher net loss reflects Research and development increase from $46.1M to $100.1M (expense), Stock-based Compensation in SGA increase from $5.9M to $23.3M (expense), Stock-based Compensation in R&D increase from $3.6M to $20.6M (expense).
| Industry: | Bio Therapeutic Drugs |
1100 Winter Street
WALTHAM
MASSACHUSETTS 02451
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com